Multi-drug-resistant tuberculosis cost-effectiveness of therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Changes made per Mahshid's request)
 
Line 30: Line 30:
[[Category:Pulmonology]]
[[Category:Pulmonology]]
[[Category:Tuberculosis]]
[[Category:Tuberculosis]]
[[Category:Infectious disease]]

Latest revision as of 18:06, 18 September 2017

Multi-drug-resistant tuberculosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multi-drug-resistant tuberculosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Multi-drug-resistant tuberculosis cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multi-drug-resistant tuberculosis cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multi-drug-resistant tuberculosis cost-effectiveness of therapy

CDC on Multi-drug-resistant tuberculosis cost-effectiveness of therapy

Multi-drug-resistant tuberculosis cost-effectiveness of therapy in the news

Blogs on Multi-drug-resistant tuberculosis cost-effectiveness of therapy

Directions to Hospitals Treating Multi-drug-resistant tuberculosis

Risk calculators and risk factors for Multi-drug-resistant tuberculosis cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]

Overview

Treatment of tuberculosis must be analysed for relative cost effectiveness of inpatient and outpatient models of care as it will benefit regions where tuberculosis is highly prevalent. Unless there is severe complications it is highly recommended to treat the TB patient in ambulatory care rather than inpatient services.[1]

Cost-effectiveness of therapy

  • According to WHO, tuberculosis takes an annual economic toll of around US$12 billion dollars worldwide. 3-4 months of work time are lot due to tuberculosis.
  • The average cost of treating a person with TB disease increases with greater resistance.
  • Direct costs (in 2010 U.S. dollars) average from $17,000 to treat drug-susceptible TB to $430,000 to treat the most drug-resistant form of the disease (XDR TB). [2]
  • When including productivity losses (e.g., lost income) experienced by patients while undergoing treatment, costs are even higher.[2]
Image obtained from CDC[2]
  • The cost of MDR-TB treatment is upto 100 times more expensive than fully sensitive patients.
  • DOTS-Plus is a cost effective approach in areas of assumed poor compliance.
  • Reduced price second line drugs must be given to the programs following the guidelines of "Green Light Committee". This could save upto 57.5% of overall budget for TB control. [3]

References

  1. Fitzpatrick C, Floyd K (2012). "A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis". Pharmacoeconomics. 30 (1): 63–80. doi:10.2165/11595340-000000000-00000. PMID 22070215.
  2. 2.0 2.1 2.2 "CDC Drug-Resistant TB".
  3. Gupta R, Kim JY, Espinal MA, Caudron JM, Pecoul B, Farmer PE; et al. (2001). "Public health. Responding to market failures in tuberculosis control". Science. 293 (5532): 1049–51. doi:10.1126/science.1061861. PMID 11463877.

Template:WH Template:WS